- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00405418
Lantus Versus Levemir Treat-To-Target (L2T3)
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
North Ryde, Australien
- Sanofi-Aventis
-
-
-
-
-
Sao Paolo, Brasilien
- Sanofi-Aventis
-
-
-
-
-
Berlin, Deutschland
- Sanofi-Aventis
-
-
-
-
-
Hoersholm, Dänemark
- Sanofi-Aventis
-
-
-
-
-
Helsinki, Finnland
- Sanofi-Aventis
-
-
-
-
-
Mumbai, Indien
- Sanofi-Aventis
-
-
-
-
-
Dublin, Irland
- Sanofi-Aventis
-
-
-
-
-
Laval, Kanada
- Sanofi-Aventis
-
-
-
-
-
Seoul, Korea, Republik von
- Sanofi-Aventis
-
-
-
-
-
Gouda, Niederlande
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Rumänien
- Sanofi-Aventis
-
-
-
-
-
Moscow, Russische Föderation
- Sanofi-Aventis
-
-
-
-
-
Stockholm, Schweden
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Schweiz
- Sanofi-Aventis
-
-
-
-
-
Belgrade, Serbien
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spanien
- Sanofi-Aventis
-
-
-
-
-
Taipe, Taiwan
- Sanofi-Aventis
-
-
-
-
-
Istanbul, Truthahn
- Sanofi-Aventis
-
-
-
-
-
Guildford, Vereinigtes Königreich
- Sanofi-Aventis
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Type 2 diabetes for at least 1 year
- Insulin naïve
- Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
- 7% ≤ HbA1c ≤ 10.5 %
- Body mass index (BMI) < 40 kg/m²
- Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Exclusion Criteria:
- Type 1 diabetes
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
- Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
- Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
- Breast-feeding
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Treatment with systemic corticosteroids in the 3 months prior to study entry
- Treatment with any investigational product in the 2 months prior to study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
- Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
- History of drug or alcohol abuse in the last year
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 1
Insulin Glargine
|
Subcutaneous injection, once a day in the evening
|
|
Aktiver Komparator: 2
Insulin Detemir
|
Subcutaneous injection, twice a day at breakfast and before dinner
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
HbA1c recorded
Zeitfenster: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Zeitfenster: On the 4 consecutive days before each visit
|
On the 4 consecutive days before each visit
|
|
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Zeitfenster: Within the week prior to baseline, week 12 and week 24
|
Within the week prior to baseline, week 12 and week 24
|
|
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Zeitfenster: All across the study
|
All across the study
|
|
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Zeitfenster: All across the study
|
All across the study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Doses of insulin glargine or insulin detemir
Zeitfenster: Daily
|
Daily
|
|
Laboratory fasting plasma glucose
Zeitfenster: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Insulinemia and fasting C-peptide level
Zeitfenster: At baseline
|
At baseline
|
|
Lipid profile
Zeitfenster: at baseline and week 24
|
at baseline and week 24
|
|
Patient reported outcomes (quality of life and treatment satisfaction)
Zeitfenster: at baseline, week 4, week 12 and at the last visit
|
at baseline, week 4, week 12 and at the last visit
|
|
Safety data: occurrence of adverse events and weight
Zeitfenster: assessed at each visit
|
assessed at each visit
|
|
Waist and hip circumferences
Zeitfenster: measured at baseline, week 12 and week 24
|
measured at baseline, week 12 and week 24
|
|
Systolic and diastolic blood pressure
Zeitfenster: measured at study entry, baseline, week 12 and week 24
|
measured at study entry, baseline, week 12 and week 24
|
|
Physical examination
Zeitfenster: performed at study entry and at last visit.
|
performed at study entry and at last visit.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Valérie Pilorget, Sanofi
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LANTU_C_00579
- EUDRACT # : 2006-000324-13
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .